Navigation Links
Keryx Biopharmaceuticals, Inc. Announces Second Quarter 2008 Financial Results
Date:8/8/2008

turing which was implemented at the end of the first quarter. We believe that the resulting organization, while lean, possesses the requisite strengths and capabilities necessary to expeditiously move Zerenex and Perifosine forward, as well as to assess additional opportunities which may enhance our product pipeline." Weiss continued, "With respect to our financial health, we expect our cash burn to be approximately $6 million to $8 million for the remaining six months of 2008, and intend to continue to focus our resources on creating value in our product portfolio."

On Monday, August 11, 2008, at 8:30am EDT, the Company will host an investor conference call during which they will provide a brief financial overview of the Company's second quarter financial results.

In order to participate in the conference call, please call 1-877-719-9788 (U.S.), 1-719-325-4769 (outside the U.S.), call-in ID: KERYX. The audio recording of the conference call will be available for replay at http://www.keryx.com, for a period of 15 days after the call.

ABOUT KERYX BIOPHARMACEUTICALS, INC.

Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important, novel pharmaceutical products for the treatment of life-threatening diseases, including renal disease and cancer. Keryx is developing Zerenex(TM) (ferric citrate), an oral, iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. Zerenex is currently in Phase 2 clinical development for the treatment of hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease. The Company is also developing KRX-0401 (perifosine), a novel, potentially first-in-class, oral anti-cancer agent that modulates Akt, a protein in the body associated with tumor survival and growth. KRX-0401 also modulates a number of other key signal transduction pathways, including the
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. Presentation Time Correction: Keryx Biopharmaceuticals Presents at 12:00pm, ET Tomorrow (Oct. 3) at William Blair & Company Small-Cap Growth Stock Conference
2. Keryx Biopharmaceuticals, Inc. Announces Poster Presentations Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) to be Presented at the Upcoming American Society of Hematology Meeting in Atlanta, Georgia
3. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
4. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
5. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
6. HEI, Inc. Announces Sale of RFID Division Assets
7. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
8. Mettler-Toledo International Inc. Announces Webcast of Presentation at Thomas Weisel Partners 2007 Healthcare Conference
9. Z Trim Announces Revocation of Gregory Halpern Severence Agreement
10. Brooke Franchise Corporation Announces Selected July Results
11. Manor Care, Inc. Announces Record Date for Special Stockholder Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... Angeldress.co.uk is a popular ... occasion outfits for worldwide clients. According to Leo, the ... opening the first flagship retail store. Moreover, it is ... company has unveiled its new range of amazing wedding ... its new products are offered at greatly discounted prices, ...
(Date:9/17/2014)... (PRWEB) September 17, 2014 There’s ... interruptions, giving girls of all ages an all-natural ... company founded by women, for women, announces the ... (http://GirlU.com) to relieve the symptoms commonly ... and irritability. , As a lifelong health ...
(Date:9/17/2014)... San Diego, CA (PRWEB) September 17, 2014 ... Dermatology in San Diego, Dr. William Groff, an expert on ... of treating it. Pearly penile papules , or PPP, ... twenties and thirties, although other men may be affected as ... head of the penis. , “While PPP is not ...
(Date:9/17/2014)... 17, 2014 A raucous childhood in ... together to form author Nancy Chovancek’s laughter-filled new book, ... a collection of short stories that prove the best ... With a positive message of empowerment and resilience, everyone ... a proven author with two books under her belt ...
(Date:9/17/2014)... GA (PRWEB) September 17, 2014 ... District (DHCHD) has implemented its CollaborNet™ Health ... exchange of patients’ health information between Coon Memorial ... Texas, and physicians in the community. , ... application to enable electronic referrals by physicians to ...
Breaking Medicine News(10 mins):Health News:Angeldress.co.uk Is Planning To Open Its First Retail Store And Offering Big Savings On Amazing Wedding Dresses 2Health News:Girl Uninterrupted® Debuts New Look for All-Natural, PMS-Relief Supplement, Launching Today 2Health News:Girl Uninterrupted® Debuts New Look for All-Natural, PMS-Relief Supplement, Launching Today 3Health News:Girl Uninterrupted® Debuts New Look for All-Natural, PMS-Relief Supplement, Launching Today 4Health News:New Video Depicts Best Treatment for PPP 2Health News:New Video Depicts Best Treatment for PPP 3Health News:Dallam-Hartley Counties Hospital District Deploys Holon's Health Information Exchange (HIE) Solution to Facilitate Improved Patient Care 2Health News:Dallam-Hartley Counties Hospital District Deploys Holon's Health Information Exchange (HIE) Solution to Facilitate Improved Patient Care 3
... 2007 A review published in Dermatologic Therapy reveals that ... the same way as women but require higher doses of ... become a growing interest in cosmetic procedures by men. Although ... male patients who seek treatment is slowly increasing. , ...
... ceremony of, facility being built to serve the western Palm ... ... Dec. 28 The Health Care District,of Palm Beach County Board ... Board of Directors recently,dedicated the 50 acres of land on which ...
... plus fluticasone therapy led to better health, large trial ... People suffering with chronic obstructive pulmonary disease (COPD) may ... risk of death within two years as well and ... new research suggests. , The conclusion is drawn ...
... Dec. 28 /PRNewswire-FirstCall/ - AlphaRx Inc. (OTC BB:ALRX,- ... for Drug Delivery,Platforms, announce that in order to ... directors, consultants and employees plan to,exercise stock options ... Lee, President and CEO, will cancel 6,000,000 options,granted ...
... NYSE Agrees to a Trading Extension of KV,s Securities until February ... ... 2008, ST. LOUIS, Dec. 28 KV Pharmaceutical Company,(NYSE: ... markets technology differentiated,branded and generic/non-branded prescription pharmaceutical products,announced today that NYSE ...
... of the Philadelphia Ronald McDonald House, will ... Ceremony on, Thursday, January 3rd; House ... PHILADELPHIA, Dec. 28 The 27,000-square-foot,three-story "Philadelphia Ronald ... its doors on Monday, January 7, 2008 - ...
Cached Medicine News:Health News:Work Begins on New Regional Hospital Medical Campus 2Health News:Work Begins on New Regional Hospital Medical Campus 3Health News:Work Begins on New Regional Hospital Medical Campus 4Health News:Drug Combo Halves Death Risk for Severe COPD Patients 2Health News:AlphaRx Officers and Directors To Exercise Options, Warrants and Retain Shares 2Health News:KV Pharmaceutical Company Announces NYSE Listing Extension 2Health News:KV Pharmaceutical Company Announces NYSE Listing Extension 3Health News:'Philadelphia Ronald McDonald House(R) at Front & Erie' Celebrates Grand Opening 2
(Date:9/17/2014)... Mindray (NYSE: MR)announced its new generation DC-70 ... has been showcased for the first time at ISUOG ... and is scheduled for availability in the U.S. market ... most efficient workhorse in the mid-range segment, the DC-70 ... optimized user experience including a gesture-sensitive touch screen, delivering ...
(Date:9/16/2014)... Sept. 16, 2014 This report analyzes the worldwide ... the following Product Segments: SPECT Systems (Includes SPECT and SPECT/CT ... report provides separate comprehensive analytics for the US, ... Europe , Asia-Pacific , ... and forecasts are provided for the period 2013 through 2020. ...
(Date:9/16/2014)... Tenn. , Sept. 16, 2014 A ... investigators has found the chemotherapy dose threshold below ... normal sperm production. The study appears in September 17 ... By clarifying which patients are at highest risk ... findings to eventually increase use of pre-treatment fertility preservation ...
Breaking Medicine Technology:Quality Exams at Your Fingertips 2Global Nuclear Medicine Imaging Equipment Industry 2Global Nuclear Medicine Imaging Equipment Industry 3Global Nuclear Medicine Imaging Equipment Industry 4Global Nuclear Medicine Imaging Equipment Industry 5Global Nuclear Medicine Imaging Equipment Industry 6Global Nuclear Medicine Imaging Equipment Industry 7Global Nuclear Medicine Imaging Equipment Industry 8Global Nuclear Medicine Imaging Equipment Industry 9Global Nuclear Medicine Imaging Equipment Industry 10Global Nuclear Medicine Imaging Equipment Industry 11Global Nuclear Medicine Imaging Equipment Industry 12Global Nuclear Medicine Imaging Equipment Industry 13Global Nuclear Medicine Imaging Equipment Industry 14Global Nuclear Medicine Imaging Equipment Industry 15Global Nuclear Medicine Imaging Equipment Industry 16Global Nuclear Medicine Imaging Equipment Industry 17Global Nuclear Medicine Imaging Equipment Industry 18Global Nuclear Medicine Imaging Equipment Industry 19Global Nuclear Medicine Imaging Equipment Industry 20Global Nuclear Medicine Imaging Equipment Industry 21Global Nuclear Medicine Imaging Equipment Industry 22Global Nuclear Medicine Imaging Equipment Industry 23Global Nuclear Medicine Imaging Equipment Industry 24Global Nuclear Medicine Imaging Equipment Industry 25Global Nuclear Medicine Imaging Equipment Industry 26Improved risk identification will aid fertility preservation in young male cancer patients 2Improved risk identification will aid fertility preservation in young male cancer patients 3Improved risk identification will aid fertility preservation in young male cancer patients 4
... (Nasdaq: VPHM ) today announced that its ... cytomegalovirus (CMV) disease in liver transplant patients has been ... being moved to the current standard of care. The ... Phase 3 study of maribavir in stem cell transplant ...
... children for acute osteomyelitis--a bacterial bone infection--an early changeover ... just as effective as continuing the IV therapy, according ... more convenient for children and families, and avoid a ... from using central catheters, such as infections or breaks ...
Cached Medicine Technology:ViroPharma Announces Discontinuation of Maribavir Phase 3 Study in Liver Transplant Patients 2ViroPharma Announces Discontinuation of Maribavir Phase 3 Study in Liver Transplant Patients 3ViroPharma Announces Discontinuation of Maribavir Phase 3 Study in Liver Transplant Patients 4Early Switch from IV to Oral Meds Is Effective for Children with Acute Bone Infection 2Early Switch from IV to Oral Meds Is Effective for Children with Acute Bone Infection 3
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: